Abstract
In myocardial ischemia, nonexocytotic noradrenaline release has been identified as underlying mechanism of ischemia-evoked noradrenaline release. Nonexocytotic noradrenaline release can be suppressed by inhibitors of the neuronal noradrenaline carrier (uptake), such as desipramine. Utilizing this pharmacological intervention the role of local noradrenaline release in the genesis of ischemia-induced ventricular arrhythmias was studied. Regional ischemia was induced in rat isolated perfused hearts by ligature of the left anterior descending coronary artery, and the venous effluent obtained during the first 2 min of reperfusion was used to measure the release of endogenous noradrenaline by high-performance liquid chromatography methods. Coronary occlusion caused ventricular fibrilation in a well reproducible manner with an incidence of 70 to 80% during a 30 min observation period. Blockade of uptake, by desipramine decreased the occurrence of ischemia-induced ventricular fibrillation to 60% (0.01 μmol/1) or 20% (0.1 μmol/l), and ventricular fibrillation was completely suppressed by 1 μmol/l desipramine. Likewise, desipramine (0.01–1 μmol/l) concentration-dependently reduced endogenous noradrenaline release during 30 min of regional myocardial ischemia. Nisoxetine, a structurally unrelated inhibitor of uptake,, also suppressed ischemia-evoked ventricular fibrillation.
In contrast to its antifibrillatory effect during regional myocardial ischemia, desipramine precipitated arrhythmias when ventricular fibrillation was induced by perfusing normoxic hearts with exogenous noradrenaline. Combination of desipramine (0.1 μmol/1) with exogenous noradrenaline (0.01 to 1 μmol/l) increased the incidence of ventricular fibrillation compared to noradrenaline perfusion alone. Under these conditions, uptake1-blockade is known to increase the extracellular concentration of the perfused noradrenaline. Finally, in the isolated, spontaneously beating papillary muscle of the left rat heart, desipramine (0.1 and 1.0 μmol/l) had no effect on the upstroke velocity of action potentials, the action potential duration and the effective refractory period.
In conclusion, the findings demonstrate that nonexocytotic noradrenaline release is an important mediator of ischemia-induced ventricular fibrillation in isolated hearts of the rat. It is also documented that uptake, inhibitors such as desipramine reveal their effects on ventricular fibrillation secondary to their action on transmembrane noradrenaline transport.
Similar content being viewed by others
References
Curtis MJ, Macleod BA, Walker MJA (1987) Models for the study of arrhythmias in myocardial ischemia and infarction: the use of the rat. J Mol Cell Cardiol 19:399–419
Curtis MJ, Pugsley MK, Walker MJA (1993) Endogenous chemical mediators of ventricular arrhythmias in ischemic heart disease. Cardiovasc Res 27:703–719
Daugherty A, Frayn KN, Redfern WS, Woodward B (1986) The role of catecolamines in the production of ischemia-induced ventricular arrhythmias in the rat in vivo and in vitro. Br J Pharmacol 87:265–277
Ebert A, Vanderbeek RB, Allgood RJ, Sabiston DC (1970) Effect of chronic cardiac denervation on arrhythmias after coronary artery ligation. Cardiovasc Res 4:141–147
Haass M, Cheng B, Richardt G, Lang RE, Schömig A (1989a) Characterization and presynaptic modulation of stimulation-evoked evocytotic co-release of noradrenaline and neuropeptide Y in guinea-pig heart. Naunyn-Schmiedeberg's Arch Pharmacol 339:71–78
Haass M, Hock M, Richardt G, Schömig A (1989b) Neuropeptide Y differentiates between exocytotic and nonexocytotic noradrenaline release in guinea-pig heart. Naunyn-Schmiedeberg's Arch Pharmacol 340:509–515
Iversen LL (1971) Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol 41: 571–591.
Kannengiesser GJ, Lubbe WF, Opie LH (1975) Experimental myocardial infarction with left ventricular failure in the isolated perfused rate heart: effects of isoproterenol and pacing. J Mol Cell Cardiol 7:135–151
Kurz T, Schömig A (1989) Extracellular sodium and chloride depletion enhances nonexocytotic noradrenaline release induced by energy deficiency in rat heart. Naunyn-Schmiedeberg's Arch Pharmacol 340:265–269
Richardt G, Lumpp U, Haass M, Schömig A (1990) Propranolol inhibits nonexocytotic noradrenaline release in myocardial ischemia. Naunyn-Schmiedeberg's Arch Pharmacol 341:50–55
Schaal SF, Wallace AG, Sealy WC (1969) Protective influence of cardiac denervation against arrhythmias of myocardial infarction. Cardiovasc Res 3:241–244
Schömig A, Richardt G (1990) Cardiac sympathetic activity in myocardial ischemia: release and effects of noradrenaline. Basic Res Cardiol 85 [Suppl. 1]:9–30
Schömig A, Fischer S, Kurz T, Richardt G, Schömig E (1987) Nonexocytotic release of endogenous noradrenaline in the ischemic and anoxic rat heart: mechanism and metabolic requirements. Circ Res 60:194–205
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kurz, T., Offner, B., Schreieck, J. et al. Nonexocytotic noradrenaline release and ventricular fibrillation in ischemic rat hearts. Naunyn-Schmiedeberg's Arch Pharmacol 352, 491–496 (1995). https://doi.org/10.1007/BF00169382
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00169382